Candel Therapeutics, Inc.
CADL
$5.02
$0.6013.58%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 11.15% | -5.41% | -18.44% | -21.70% | -2.68% |
| Gross Profit | -11.15% | 5.41% | 18.44% | 21.70% | 2.54% |
| SG&A Expenses | 16.99% | 9.66% | 4.91% | -0.06% | -1.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.53% | 0.57% | -9.41% | -14.13% | -2.89% |
| Operating Income | -13.53% | -0.57% | 9.41% | 14.13% | 2.81% |
| Income Before Tax | 56.40% | 55.72% | -5.92% | -45.44% | -63.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 56.40% | 55.72% | -5.92% | -45.44% | -63.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.40% | 55.72% | -5.92% | -45.44% | -63.49% |
| EBIT | -13.53% | -0.57% | 9.41% | 14.13% | 2.81% |
| EBITDA | -14.12% | -0.64% | 9.68% | 14.58% | 3.06% |
| EPS Basic | 68.53% | 60.30% | -2.93% | -33.80% | -57.70% |
| Normalized Basic EPS | 69.50% | 61.22% | -2.37% | -33.56% | -56.48% |
| EPS Diluted | 67.60% | 59.34% | -4.19% | -33.80% | -57.70% |
| Normalized Diluted EPS | 68.83% | 60.54% | -3.27% | -33.56% | -56.48% |
| Average Basic Shares Outstanding | 60.26% | 44.94% | 27.51% | 9.43% | 3.81% |
| Average Diluted Shares Outstanding | 63.83% | 48.60% | 31.20% | 9.43% | 3.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |